

Key ASH Presentations Issue 2, 2011

Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment

For more visit ResearchToPractice.com/5MJCASH2011

Research To Practice®

CME INFORMATION

OVERVIEW OF ACTIVITY

The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for hematologic cancer.

LEARNING OBJECTIVES

- Educate patients receiving fludarabine-based induction therapy, with or without cyclophosphamide, about the risk of secondary myeloid neoplasia.
- Consider long-term safety events in the selection of initial treatment for CLL.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Bruce D Cheson, MD Professor of Medicine Head of Hematology Director of Hematology Research Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC

Advisory Committee: Allos Therapeutics, Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Millennium Pharmaceuticals Inc; Consulting Agreement: Millennium Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS - The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Seattle Genetics.

Last review date: January 2011 Expiration date: January 2012



To go directly to slides and commentary, <u>click here</u>.

It's no secret that the anti-CD20 antibody rituximab has profoundly affected clinical research and management approaches in B-cell neoplasms, and in 2010 we heard about two more landmark trials that help to expand our knowledge of this very interesting agent. First, at ASCO the PRIMA study demonstrated that two years of R maintenance after prior induction with R/chemo delayed disease progression, and the ASH update of this historic study further solidified these outcomes with more follow-up. The second recent important data set came from an **Intergroup trial** that was just presented at ASH. The study randomly assigned patients with asymptomatic nonbulky advanced FL to either rituximab — for what turned out to be two years — or watch and wait (or as our prostate cancer colleagues call it, watch and worry). The trial showed that R led to a substantial delay in progression and in the need for further treatment (usually chemo).

Both of these data sets have sparked considerable debate, and as promised, last Friday in our Miami recording studio I asked the eight distinguished faculty members who participated in our clinical investigator Think Tank the bottom line on these and other seminal ASH data sets:

1. PRIMA: R maintenance after R/chemo

All of the investigators except the always free-thinking Dr Cheson offer but do not insist that patients receive two years of R maintenance.

2. Intergroup study: R versus watch and wait

None of the faculty believe that using R earlier substantially changes the natural history of the disease or overall survival, although it is important to note that there were only 21 total deaths reported in the Intergroup study and less than three years of follow-up. The Think Tank group did acknowledge that many patients find a delay in disease progression appealing in return for the modest and unchemo-like risks of this treatment.

For all the good that R has done, FL and CLL are still not curable and a litany of approaches are being evaluated in these diseases to offer patients even more. At ASH many presentations focused on other promising agents, and at our Think Tank I asked the faculty which ones they found most exciting. Here are some of their thoughts and key related data sets.

Lenalidomide

At ASH <u>Alessandra Ferrajoli</u> presented some interesting data on lenalidomide in combination with rituximab for patients with relapsed and refractory CLL. The study demonstrated a 64 percent overall response rate, and the Think Tank faculty showed considerable interest in new trials evaluating this combination up front as a means to potentially avoid the <u>increased incidence of therapy-related myeloid neoplasia</u> associated with FC and particularly FCR reported at ASH.

Bortezomib

A much-awaited ASH presentation by **Bertrand Coiffier** reported better PFS, response rate and time to next lymphoma treatment when bortezomib was added to rituximab in FL, but this study did not meet the primary endpoint of a 33 percent improvement in PFS. Ongoing cooperative trials are looking at the agent in the up-front setting, and there was uncertainty among the faculty as to whether these studies will demonstrate an acceptable benefit-risk ratio.

Small molecules

At the Think Tank Brad Kahl presented a patient responding to a new agent, CAL 101, and perhaps not surprisingly there were encouraging data <u>(click here to view</u> **abstract)** at ASH on this oral, relatively nontoxic PI3 kinase inhibitor and several other small molecules targeting the CD20 pathway.

Next up on this series, ASH data sets on a new generation of BCR-ABL TKIs in CML.

Neil Love, MD **Research To Practice** Miami, Florida

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice designates each educational activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in each activity.

This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Seattle Genetics.

Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131

This email was sent to you by Dr Neil Love and Research To Practice. To unsubscribe to future email requests and announcements, **click here**. To unsubscribe from all email communications, including CME/CNE activities sent by Research To Practice, **click here**. To update your information on our current distribution lists, **click here**.

Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment

Presentation discussed in this issue

Smith MR et al. Increased incidence of therapy related myeloid neoplasia (t-MN) after initial therapy for CLL with fludarabine-cyclophosphamide (FC) vs fludarabine (F): Long-term follow-up of US Intergroup study E2997. *Proc ASH* 2010; Abstract 924.

Slides from an ASH 2010 presentation and comments from an interview with Bruce D Cheson, MD (12/23/10)

Increased Incidence of Therapy-Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) vs Fludarabine (F): Long-Term Follow-Up of US Intergroup Study E2997


Smith MR et al. Proc ASH 2010; Abstract 924.

> Research To Practice®

Background

- Therapy-related myeloid neoplasia (t-MN) is a serious, long-term consequence of conventional chemotherapy, such as alkylating agents, topoisomerase-II inhibitors, and antimetabolites.
- Combination fludarabine and cyclophosphamide, when compared to fludarabine alone, led to higher complete and overall response rates and longer progression-free survival in Phase III E2997 trial (*J Clin Oncol* 2007;25(7):793).
- Combination therapy also caused more myelosuppression, which could lead to greater long-term effects on myeloid hematopoietic function, including t-MN.
- A follow-up of study E2997, examining the incidence of t-MN, is presented here.

Smith MR et al. Proc ASH 2010; Abstract 924.



Research

To Practice®

Patient Characteristics

Characteristic	Patients (N = 278)
Median follow-up	6.4 years
Cases of t-MN, n (%)	
Total	13 (4.7%)
After FC (N = 141)	9 (6.4%)
After F (N = 137)	4 (2.9%)
Rate of t-MN at 7 years	
After FC (N = 141)	8.2%
After F (N = 137)	4.6%
Median time from initial therapy to t-MN diagnosis	5 years

Characteristics of Patients with t-MN

Characteristics	FC (n = 9)	F (n = 4)
Additional therapy prior to t-MN		
No	7	1
Yes	2	3
IgV _H gene status		
Mutated	7	1
Unmutated	0	3
Data not available	2	0

For more visit ResearchToPractice.com/5MJCASH2011

Conclusions

- Higher incidence of t-MN was observed after combination therapy with FC than after single-agent F.
- t-MN after FC occurred most often without additional therapy and in IgV_H-mutated CLL, which is associated with a more favorable outcome.
- The increased incidence of t-MN after FC, usually in the absence of additional treatment, suggests that FC is more leukemogenic than F alone.
- This finding emphasizes a need for longer follow-up of toxicity and survival before concluding that combination FC is preferable to single-agent F as the chemotherapy backbone for initial therapy of both low- and high-risk CLL.

Smith MR et al. Proc ASH 2010; Abstract 924.

Research To Practice®

Investigator Commentary: Incidence of Therapy-Related Myeloid Neoplasia with FC vs F as Initial Therapy for CLL

Several different therapies are effective for the initial treatment of CLL, including fludarabine/rituximab (FR), fludarabine/cyclophosphamide/ rituximab (FCR) and bendamustine-based therapy. However, it is unclear which is the optimal regimen.

FCR versus FR is currently being compared in a large Intergroup trial. One of the concerns of using alkylating agents in patients with CLL is the potential for increased secondary diseases, such as myeloid neoplasia. In this study from the Eastern Cooperative Oncology Group, they found a slight increase in the number of patients who developed therapyrelated myeloid neoplasia with FC versus fludarabine alone. The numbers were small, and longer follow-up is needed to determine whether the impression that FC is more leukemogenic is valid, because FCR is widely used as the initial treatment for CLL.

Interview with Bruce D Cheson, MD, December 23, 2010 Research To Practice®